Long‐term off‐label dupilumab in pediatric atopic dermatitis: A case series
- 18 October 2018
- journal article
- research article
- Published by Wiley in Pediatric Dermatology
- Vol. 36 (1) , 85-88
Abstract
Background/Objectives: Clinical trials of dupilumab have shown efficacy in treating moderate‐to‐severe atopic dermatitis (AD) in adult patients. While a phase 2 trial of dupilumab has shown efficacy and safety in children, the medication awaits Food and Drug Administration (FDA) approval, and off‐label use is limited by dosing currently available to adults. We present this case series to describe the efficacy and safety profile of off‐label dupilumab use in six pediatric patients treated by one provider in a private practice.Methods: We conducted a retrospective chart review of all patients under the age of 18 receiving dupilumab for AD. Two dosing regimens were used as follows: adult dose for patients ≥ 40 kg and half dose for those < 40 kg. We recorded the investigator's global assessment (IGA) and body surface area (BSA) prior to dupilumab initiation and following treatment. All patients were warned of potential side effects including injection site reaction, conjunctivitis, increased risk of infection, and lack of information about use in children.Results: Six pediatric patients were identified with an average age of 10.8 years (range: 7‐15). All patients had a decrease in IGA of at least 2 points using biweekly 300 or 150 milligram (mg) doses for an average treatment duration of 8.5 months (range: 6‐11). Three patients (50%) had an IGA of 1 after treatment. No side effects were reported.Conclusions: Dupilumab appears to be an effective treatment for AD in pediatric patients. Optimal dose and delivery have yet to be determined.Keywords
This publication has 10 references indexed in Scilit:
- Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysisInternational Immunopharmacology, 2018
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2016
- Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)Journal of the American Academy of Dermatology, 2016
- Dupilumab: a milestone in the treatment of atopic dermatitisThe Lancet, 2016
- Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)+ TH2/TH1 cell imbalance, whereas adults acquire CLA+ TH22/TC22 cell subsetsJournal of Allergy and Clinical Immunology, 2015
- Guidelines of care for the management of atopic dermatitisJournal of the American Academy of Dermatology, 2014
- New insights into the epidemiology of childhood atopic dermatitisAllergy, 2013
- Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilizationPediatric Allergy and Immunology, 2013
- Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitisJournal of Allergy and Clinical Immunology, 2012